Scientists at Xi’an Jiaotong-Liverpool University and Nanjing University have engineered a novel nanoparticle system integrating the biodegradable polymer PLGA with blood protein albumin to form stable ‘supraparticles’ exhibiting superior drug-loading capacity and colloidal stability. These hybrid nanoparticles achieve encapsulation of up to 40% doxorubicin by weight, a marked improvement over current formulations like Doxil. Preclinical studies demonstrated reduced side effects and stable release profiles. This advance may transform chemotherapy delivery by improving therapeutic efficacy while minimizing off-target toxicity.